+

WO2016167527A1 - Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci - Google Patents

Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci Download PDF

Info

Publication number
WO2016167527A1
WO2016167527A1 PCT/KR2016/003818 KR2016003818W WO2016167527A1 WO 2016167527 A1 WO2016167527 A1 WO 2016167527A1 KR 2016003818 W KR2016003818 W KR 2016003818W WO 2016167527 A1 WO2016167527 A1 WO 2016167527A1
Authority
WO
WIPO (PCT)
Prior art keywords
white rice
acid
pharmaceutical composition
extract
cosmetic composition
Prior art date
Application number
PCT/KR2016/003818
Other languages
English (en)
Korean (ko)
Inventor
최신욱
홍인기
석지현
김힐
배형진
김은지
Original Assignee
주식회사 래디안
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 래디안 filed Critical 주식회사 래디안
Priority to CN201680013060.4A priority Critical patent/CN107405272B/zh
Publication of WO2016167527A1 publication Critical patent/WO2016167527A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a cosmetic composition for skin regeneration and a pharmaceutical composition for treating wounds containing sinafic acid (sinapic acid) or white rice extract containing the same as an active ingredient.
  • the skin system is an organ that covers the outside of the human body and has various functions such as body temperature control and a barrier to the external environment.
  • This skin is composed of three layers of subcutaneous fat layer, dermis and epidermis from the innermost side.
  • the subcutaneous fat layer is composed of fat cells and is located at the innermost part of the skin layer.
  • the dermis which is located above the subcutaneous fat layer, is composed of matrix proteins such as collagen fibers and elastic fibers, and includes blood vessels, nerves, and sweat glands.
  • the outermost epidermis is mostly composed of keratinocytes of stratified squamous epithelium.
  • Dermabrasion is a procedure that induces the production of new epidermis and stimulates the production of collagen fibers in the dermis, which is used for the treatment of acne, scars, wrinkles, pigmented lesions, and enlarged pores.
  • Such dermabrasion is a case of artificially creating a wound on the skin, which refers to any state in which tissue continuity is destroyed by external pressure.
  • the dermis When wounds occur on the skin, the dermis is first regenerated and at the same time the epidermis is regenerated. More specifically, when the skin is injured, mast cells in the dermis secrete histamine to expand blood vessels, and inflammatory cells (white blood cells, platelets, etc.) gather into the expanded blood vessels. When leukocytes secrete cytokines among inflammatory cells, they activate fibroblasts, which maintain the elasticity of the dermis, secreting collagen and mucopolysaccharides. The epidermis torn by the wound then activates genes involved in cell migration and consequently the epidermis regenerates.
  • EGF epidermal growth factor
  • EGF has been reported to promote wound healing of the skin, cornea, and mucous membranes through various studies. In addition, it has been reported that EGF prevents the development of scars, a product of adult wound healing.
  • various cytokines are known to be involved in wound healing. For example, there is transforming growth factor- ⁇ (TGF- ⁇ ).
  • TGF- ⁇ transforming growth factor- ⁇
  • the TGF- ⁇ is a substance involved in the growth and differentiation of various cells, such as growth regulation, regulation of immune response, stimulation of bone formation, induction of cartilage-specific macromolecules, promotion of wound healing, etc.
  • TGF- ⁇ transforming growth factor- ⁇
  • the TGF- ⁇ is a substance involved in the growth and differentiation of various cells, such as growth regulation, regulation of immune response, stimulation of bone formation, induction of cartilage-specific macromolecules, promotion of wound healing, etc.
  • Several complex functions have been reported (Bennett, NT et al., Am. J. Surg. 165: 728, 1993).
  • the present invention as a plant-derived material, to discover the new components that can regenerate the skin, heal the wound, to develop into a cosmetic composition for skin regeneration and pharmaceutical composition for wound treatment.
  • the present invention provides a cosmetic composition for skin regeneration characterized in that it contains sinapic acid (sinapic acid) as an active ingredient.
  • the present invention also provides a cosmetic composition for skin regeneration comprising a plant extract containing sinafic acid (sinapic acid) as an active ingredient.
  • the plant extract preferably white rice ( Cynanchum atratum ) extract.
  • the white rice ( Cynanchum atratum ) extract is preferably an extract obtained from white rice using any one selected from ethanol, dichloromethane and ethyl acetate as a solvent.
  • the cosmetic composition for skin regeneration of the present invention may include components conventionally used in cosmetic compositions in addition to plant extracts containing sinafic acid or sinafic acid, for example, antioxidants, stabilizers, and solubilizers. And conventional adjuvants and carriers such as vitamins, pigments and flavorings.
  • the cosmetic composition is, for example, a solution, a suspension, an emulsion, a paste, a gel, a cosmetic composition, a lotion, a powder, a soap, a surfactant-containing cleansing, an oil, a powder foundation, It may have any formulation selected from the group consisting of emulsion foundations, wax foundations, and sprays.
  • the formulation of the cosmetic composition of the present invention is a paste or gel
  • animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component when the formulation of the cosmetic composition of the present invention is a powder or a spray, and in particular, in the case of a spray, additionally chlorofluoro Propellants such as hydrocarbon, propane / butane or dimethyl ether.
  • the formulation of the cosmetic composition of the present invention is a solution or emulsion
  • water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan can be used.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspending agents such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, Aluminum metahydroxy, bentonite, agar or tragacanth and the like can be used.
  • the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent
  • a surfactant-containing cleansing agent as a carrier component, an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, and sarcosy Nates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters can be used.
  • the present invention provides a pharmaceutical composition for the treatment of wounds, comprising sinafic acid (sinapic acid) as an active ingredient.
  • the present invention provides a pharmaceutical composition for treating wounds, comprising a plant extract containing sinapic acid as an active ingredient.
  • the plant extract is preferably white rice ( Cynanchum atratum ) may be an extract.
  • the white rice ( Cynanchum atratum ) extract may be, for example, an extract obtained from white rice using any one selected from ethanol, dichloromethane and ethyl acetate as a solvent.
  • the pharmaceutical composition for wound treatment of the present invention may further comprise a carrier, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
  • the pharmaceutical composition for wound treatment of the present invention may be formulated in the form of external preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and sterile injectable solutions according to conventional methods, creams, Gels, patches, sprays, ointments, warnings, lotions, linings, pasta or cataplasma may also be prepared and used as a pharmaceutical composition for external application of the skin, but is not limited thereto.
  • the carrier, excipient and diluent may be, for example, lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, Gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oils, the choice of which More than one can be used.
  • the solid preparation for oral administration may be, for example, tablets, pills, powders, granules, capsules, starch, calcium carbonate, sucrose or lactose. (lactose), one or more selected from gelatin may be included.
  • liquid preparations for oral administration may be, for example, suspensions, liquid solutions, emulsions, and syrups, and one selected from water, liquid paraffin, wetting agents, sweeteners, fragrances, and preservatives. The above may be included.
  • the preparation for parenteral administration may be, for example, a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized agent, and a non-aqueous solvent and a suspension as propylene glycol.
  • a sterile aqueous solution a non-aqueous solvent, a suspension, an emulsion, a lyophilized agent, and a non-aqueous solvent and a suspension as propylene glycol.
  • Vegetable oils such as polyethylene glycol, olive oil, and injectable esters such as ethyloleate may be included.
  • the dosage of the pharmaceutical composition for wound treatment of the present invention may be determined in consideration of the method of administration, the age, sex and weight of the recipient, and the severity of the disease.
  • the pharmaceutical composition for wound treatment of the present invention may be administered one or more times at 0.0000001 to 100 mg / kg body weight per day based on the active ingredient.
  • the above dosage is merely an example for illustration, and may be changed by a doctor's prescription according to the condition of the taking person.
  • Synaptic (sinapic aicd) of the present invention or a cosmetic composition for skin regeneration and wound treatment containing a plant extract containing the same as an active ingredient exhibits excellent cell regeneration effect and wound treatment effect.
  • 1 is a graph measuring cell viability and growth ability according to solvent type and concentration of white rice extract.
  • Figure 2 is a graph measuring the cell migration capacity according to the type and concentration of white rice extract solvent.
  • Figure 3 is a graph measuring the expression inhibition ability of 'TNF- ⁇ ' according to the type and concentration of white rice extract solvent.
  • Figure 4 is a graph measuring the inhibitory ability of 'PGE 2 ' expression according to solvent type and concentration of white rice extract.
  • Figure 5 is a graph measuring the inhibitory ability of 'IL-2' expression according to solvent type and concentration of white rice extract.
  • Figure 6 is a graph measuring the inhibitory ability of 'iNOS' and 'COX-2' expression according to solvent type and concentration of white rice extract.
  • 10 is a graph measuring the inhibition of expression of 'TNF- ⁇ ' according to the concentration of sinafic acid (sinapic acid).
  • Figure 11 is a graph measuring the inhibition of 'IL-2' expression according to the concentration of sinapic acid (sinapic acid).
  • Figure 13 is a graph measuring the wound area according to the addition of white rice extract.
  • white rice extract was prepared.
  • the dried white rice outpost was purchased and prepared into powder using a grinder.
  • the white rice powder was extracted using '70% ethanol ', '99 .5% dichloromethane' and '99% ethyl acetate 'as extraction solvents. At this time, the amount of each extraction solvent was 5-20 ml per 1 g of the dry weight of the white rice powder.
  • the extraction was carried out for 3 hours at room temperature for extraction. After extraction, the extract was recovered using filter paper. The recovered extracts were each concentrated using a rotary vacuum concentrator, and then used in the following experiment.
  • the cytotoxicity was determined by performing an 'MTT assay' on the white rice extract prepared in Preparation Example 1.
  • HaCaT Human-derived keratinocytes
  • Solvent type Solvent Concentration ( ⁇ g / mL) 70% ethanol 25 50 100 200 99.5% dichloromethane One 5 10 25 99% ethyl acetate One 5 10 25
  • Keratinocytes were inoculated in 24 well plates at a concentration of 1 ⁇ 10 5 cells / ml and incubated, followed by scraping the cells using a 200 ⁇ l pipette tip. Thereafter, 70 ⁇ g of ethanol white rice extract having no cytotoxicity in Experimental Example 1, 25 ⁇ g / ml, 50 ⁇ g / ml, 99.5% dichloromethane 5 ⁇ g / ml, 99 ⁇ g ethyl acetate 5 ⁇ g / ml, respectively, were added 72 Cell migration was measured for time. At this time, as a control group was used EGF known as a substance to increase the cell mobility.
  • EGF EGF known as a substance to increase the cell mobility.
  • the white rice extract had a superior cell mobility compared to the control EGF, it was confirmed that the best cell mobility in 50 ⁇ g / ml 70% ethanol white rice extract (Fig. 2).
  • HaCaT Human derived keratinocytes
  • HaCaT Human keratinocytes
  • aCaT Human keratinocytes
  • 25 ⁇ g / ml, 50 ⁇ g / ml, 99.5% dichloromethane 5 ⁇ g / ml, and 99 ⁇ g ethyl acetate 5 ⁇ g / ml of the 70% ethanol white rice extract prepared in Preparation Example 1 were added to the well plates, respectively. Cultured for 24 hours, and the amount of PGE 2 secreted in the culture was measured by immunoassay. At this time, 1 ⁇ M of dexamethasone (dexamethasone) was used as a positive control.
  • HaCaT Human derived keratinocytes
  • HaCaT Human derived keratinocytes
  • HaCaT human-derived keratinocytes
  • HaCaT human-derived keratinocytes
  • Keratinocytes were inoculated in a 24 well plate at a concentration of 1 ⁇ 10 5 cells / ml and incubated, followed by scraping the cells using a 200 ⁇ l pipette tip. Sinapic acid was then added to the well plates and cell migration was measured for 72 hours. As a control, EGF known to enhance cell migration capacity was used.
  • HaCaT Human-derived keratinocytes
  • HaCaT Human-derived keratinocytes
  • HaCaT Human-derived keratinocytes
  • 5-week-old male SD rats were used among rodents widely used for toxicity and drug efficacy tests, and 5-week-old male SD rats were anesthetized to produce a wound model, and after depilation, 70% ethanol and povidone The skin was disinfected using.
  • a 3 cm x 3 cm scalpel on one side of the spinal cord was used to induce a wound and to remove the dermis. Thereafter, 0.5% (w / v), 1% (w / v), and 2% (w / v) white rice extracts were applied to the wound-inducing area, respectively, and then stably dressed.
  • Hematoxylin & Eosin (H & E) staining was performed to evaluate the histopathological efficacy of skin wound healing of white rice extracts, which were then read using an optical microscope.
  • Example 1 Skin regeneration containing white rice extract as an active ingredient Cream Cosmetics Composition
  • a cream-type cosmetic composition for skin regeneration containing white rice extract as an active ingredient.
  • Ingredients comprising a white rice extract of 2% solids content (w / v) were mixed according to the contents of Table 4 below to prepare a creamy cosmetic composition for skin regeneration.
  • Example 2 Wound therapeutic pharmaceutical composition containing white rice extract as an active ingredient
  • Solid content of the present invention was prepared by mixing the ingredients containing a white rice extract of 2% (w / v) according to the content of Table 5, to prepare a pharmaceutical composition (ointment) for wound treatment.
  • compositions for skin regeneration containing sinafic acid as an active ingredient.
  • Components comprising a 2% (w / v) sinaflic acid suspension were mixed according to the contents of Table 6 below to prepare a creamy cosmetic composition for skin regeneration.
  • composition for wound treatment containing cinnamic acid as an active ingredient.
  • the solids content of the present invention was prepared by mixing the components containing 2% (w / v) sinaflic acid suspension according to the content of Table 7, to prepare a pharmaceutical composition (ointment) for wound treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition cosmétique pour la régénération de la peau et une composition pharmaceutique pour le traitement des plaies, ces compositions contenant en tant que principe actif de l'acide sinapique ou des extraits de Cynanchum atratum renfermant celui-ci. La composition cosmétique pour la régénération de la peau et la composition pharmaceutique pour le traitement des plaies de la présente invention, qui contiennent de l'acide sinapique ou des extraits de Cynanchum atratum renfermant celui-ci, permettent de prévenir l'apparition d'une inflammation sur la peau et présentent en même temps d'excellents effets de reproduction cellulaire et de traitement des plaies.
PCT/KR2016/003818 2015-04-13 2016-04-12 Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci WO2016167527A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680013060.4A CN107405272B (zh) 2015-04-13 2016-04-12 包含作为白薇提取物的指标成分的芥子酸或具有其的白薇提取物的皮肤再生用化妆品组合物及伤口治疗用药学组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0051584 2015-04-13
KR1020150051584A KR101768870B1 (ko) 2015-04-13 2015-04-13 백미 추출물의 지표성분인 시나프산 또는 이를 함유하는 백미 추출물을 함유하는 피부재생용 화장료 조성물 및 상처 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
WO2016167527A1 true WO2016167527A1 (fr) 2016-10-20

Family

ID=57127067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003818 WO2016167527A1 (fr) 2015-04-13 2016-04-12 Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci

Country Status (3)

Country Link
KR (1) KR101768870B1 (fr)
CN (1) CN107405272B (fr)
WO (1) WO2016167527A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101649450B1 (ko) * 2015-08-19 2016-08-18 이상철 피부 상처 치료조성물
KR101966374B1 (ko) 2017-11-28 2019-04-05 이노팜 주식회사 침향 추출물 및 베타글루칸(β-Glucan)을 포함하는 상처 치료 촉진용 조성물
KR102010404B1 (ko) 2018-06-04 2019-08-13 주식회사 익스플즌 피부 재생 효과를 갖는 화장료 조성물 및 이를 이용한 화장품
CN109106634A (zh) * 2018-08-01 2019-01-01 广州皓雨投资有限公司 一种含有金箔和红参提取物的组合物、睡眠面膜及其制备方法
CN109106664A (zh) * 2018-08-13 2019-01-01 广州皓雨投资有限公司 具有保湿舒缓修护功效的组合物、面膜及其制备方法
KR102125625B1 (ko) * 2018-11-27 2020-06-22 서상준 아토피성 질환의 완화 및 치료용 패드
CN110227057A (zh) * 2019-06-10 2019-09-13 北京恒峰铭成生物科技有限公司 一种毛发再生的啫喱膏及其制备方法
CN110946888A (zh) * 2019-12-26 2020-04-03 北京农学院 白薇在制备保护动物肠道炎症的药物中的应用
CN111012813A (zh) * 2019-12-26 2020-04-17 北京农学院 白薇在制备保护动物肠道损伤的药物的应用
KR102141641B1 (ko) * 2020-01-31 2020-08-06 주식회사 래디안 인간지방 유래 중간엽 줄기세포로부터 모유두세포로의 분화방법
KR102285995B1 (ko) * 2020-10-27 2021-08-05 주식회사 메디포 백미 추출물 및 피토스테롤을 유효성분으로 포함하는 화상 또는 창상의 예방 또는 치료용 조성물
KR102348275B1 (ko) * 2021-04-27 2022-01-06 주식회사 래디안 피부 자극 완화 및 항염 효능을 갖는 화장료 조성물
KR102553868B1 (ko) * 2021-05-03 2023-07-07 수바이오 주식회사 점착성 투명 다기능 창상피복재의 제조방법
KR20240004022A (ko) 2022-07-04 2024-01-11 주식회사 래디안 식물의 캘러스 유도 방법 및 그 추출물을 포함하는 조성물
KR102606838B1 (ko) 2023-01-20 2023-11-29 그린코스 주식회사 식물 뿌리 추출물을 포함하는 항산화 및 항염증 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020029181A (ko) * 2000-10-12 2002-04-18 성재갑 로로통 추출물, 백미 추출물에서 선택되는 1종 이상을유효성분으로 함유하는 화장료 조성물
KR20090118948A (ko) * 2007-03-06 2009-11-18 코그니스 아이피 매니지먼트 게엠베하 시나핀산 유도체의 용도 및 그러한 유도체를 포함하는 조성물
KR20110017729A (ko) * 2009-08-14 2011-02-22 주식회사 래디안 2,4-다이하이드록시아세토페논 또는 이를 함유하는 백미 추출물을 포함하는 피부 자극 완화용 화장료 조성물
KR20120084504A (ko) * 2011-01-20 2012-07-30 부산대학교 산학협력단 시나핀산을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 약학조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437117A1 (fr) * 2002-12-19 2004-07-14 Cognis France S.A. Utilisation d'acide sinapique ou/et de ses dérivés
KR101505903B1 (ko) 2012-06-11 2015-03-25 한국생명공학연구원 감수 추출물，이의 분획물 또는 이로부터 분리한 디테르펜 화합물을 유효성분으로 함유하는 창상 치료 또는 피부 활성용 약학적 조성물
KR20140114617A (ko) 2013-03-19 2014-09-29 전남대학교산학협력단 커큐민을 함유한 상처치료용 도포형 겔 및 그 제조방법
CN103520328B (zh) * 2013-10-31 2014-12-24 天津中医药大学 一种复方中药痤疮凝胶及其制备方法
CN103550327A (zh) * 2013-11-01 2014-02-05 刘增慧 一种用于创伤愈合的药剂的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020029181A (ko) * 2000-10-12 2002-04-18 성재갑 로로통 추출물, 백미 추출물에서 선택되는 1종 이상을유효성분으로 함유하는 화장료 조성물
KR20090118948A (ko) * 2007-03-06 2009-11-18 코그니스 아이피 매니지먼트 게엠베하 시나핀산 유도체의 용도 및 그러한 유도체를 포함하는 조성물
KR20110017729A (ko) * 2009-08-14 2011-02-22 주식회사 래디안 2,4-다이하이드록시아세토페논 또는 이를 함유하는 백미 추출물을 포함하는 피부 자극 완화용 화장료 조성물
KR20120084504A (ko) * 2011-01-20 2012-07-30 부산대학교 산학협력단 시나핀산을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 약학조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOU, HONGXIANG ET AL.: "Sinapic Acid Esters and A Phenolic Glycoside from Cynanchum Hancockianum", PHYTOCHEMISTRY, vol. 32, no. 5, March 1993 (1993-03-01), pages 1283 - 1286, XP055324078 *

Also Published As

Publication number Publication date
CN107405272B (zh) 2023-06-09
KR101768870B1 (ko) 2017-08-17
KR20160121847A (ko) 2016-10-21
CN107405272A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
WO2016167527A1 (fr) Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci
WO2022071643A1 (fr) Nouvelle composition comprenant un exosome dérivé d'edelweiss en tant que principe actif
WO2017123022A1 (fr) Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
KR101878069B1 (ko) 생약 혼합물의 추출물과 편백 오일을 함유하는 여드름 또는 아토피 피부염의 예방 또는 치료용 조성물
WO2015053460A1 (fr) Composition cosmétique contenant un liquide de baies de ginseng à fermentation de pleurotus ferulae
WO2013089449A1 (fr) Composition cosmétique contenant la pellicule biologique d'escargots nourris avec du ginseng rouge et procédé de fabrication de cette composition
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
WO2017135556A1 (fr) Composition contenant du gdf11 et son utilisation
WO2018174453A1 (fr) Composition contenant un extrait de cirsium ja p onicum en tant que principe actif pour stimuler la mélanogenèse
WO2018164369A1 (fr) Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif
WO2021112398A1 (fr) Composition comprenant de la vitamine c
WO2017200288A1 (fr) Composition pour le blanchiment de la peau, la prévention du vieillissement de la peau ou l'amélioration des rides de la peau, comprenant un extrait médicinal oriental naturel en tant que substance active
WO2017043670A1 (fr) Composition cosmétique contenant un extrait de cédrat
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
WO2018143692A1 (fr) Composition pharmaceutique comprenant comme principe actif de la poudre d'écorce primaire d'orme ou de racine d'ulmus davidiana afin de traiter des plaies et de régénérer la peau
KR100530843B1 (ko) 동충하초 추출물을 유효성분으로 포함하는 항염 조성물
WO2011053007A2 (fr) Composition pour supprimer le rétrécissement des pores ou la sécrétion de sébum comprenant un extrait de potentilla chinensis
WO2021075929A1 (fr) Composition comprenant un extrait de feuille d'artemisia princeps, pour le soulagement de lésions cutanées
WO2019245332A1 (fr) Composition pharmaceutique pour traiter une plaie ou activer la peau, contenant du bêta-glucane, de la glycitine et de la 4', 6,7-triméthoxyisoflavone
WO2019139403A1 (fr) Composition contenant de la séricine, un extrait de torilis japonica et un extrait de viscum album pour la régénération de la peau, l'apaisement de la peau ou la cicatrisation des plaies
WO2017119535A1 (fr) Composition anti-âge comprenant de la carnosine, peptide de soja, et extrait d'andrographis paniculata
WO2022265150A1 (fr) Milieu de culture riche en exosomes de cellules souches immortalisées et composition fonctionnelle comprenant de la toxine botulique
WO2016171482A1 (fr) Composition cosmétique comprenant un extrait d'apitoxine, et son procédé de fabrication
WO2021002561A1 (fr) Micro-aiguille contenant un extrait de symplocarpus foetidus
WO2019190010A1 (fr) Composition d'extraction éthanolique de citri unshius pericarpium, magnolia officinalis, corydalis remota et acacia catechu, ayant des effets d'amélioration des rides cutanées, d'hydratation, d'antioxydation ou de réduction d'inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16780250

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16780250

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载